Publications

Publish innovative results and secure attention.

Related to the topic, you will find a selection of articles that have been published in international journals with peer-review by the company's founder as initiator.

From the idea to worldwide approval.

For products that have already received market approval, we conduct clinical studies in which the medical benefits and safety of the products are presented. We publish the study results with you in international high-ranking journals and support you in ensuring that your product is eligible for reimbursement by health insurers (see also list of medical devices). Our customers use the study results to efficiently market their medical product.

Recently, we have shown the benefit and safety of a standing stand in an international retrospective clinical evaluation. The publication is very positively perceived by the research community as well as efficiently used by our customer to market the medical device. We also successfully published the results of a prospective study of a novel non-invasive medical device that enabled patients with an elevated cardiovascular risk profile to lose weight over a long period of time (more than 2 years).

List of publications
  • Schmidt-Lucke C, Käferle J, Rydh Berner BM, Ahlborg L, Hansen HM, Skjellvik Tollefsen U, Thon T, Damkjær Moen R, Pekanovic A, Tornberg ÅB, Lauruschkus K. Effect of assisted walking-movement in patients with genetic and acquired neuromuscular disorders with the motorised Innowalk device: an international case study meta-analysis. PeerJ. 2019
  • von Seck P, Sander FM, Lanzendorf L, von Seck S, Schmidt-Lucke A, Zielonka M, Schmidt-Lucke C. Persistent Weight Loss with a Non-invasive Novel Medical Device to Change eating Behavior In Obese Individuals With High-risk Cardiovascular Risk Profile. PLoS ONE. 2017

From the patient to the lab and forward again to the clinic.

Translational studies answer questions that affect our patients, at the boundary between basic research and practical application. Curiosity, accuracy, precise and sound knowledge and a sense of a relevant current issue characterize academic research with practical applicability. Vascular regeneration is critically influenced by cells circulating in the bloodstream and is the basis of proper organ function. This work has been widely cited and reproduced internationally.

List of publications
  • Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, Zeiher AM. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005
  • Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Rossig L, Heeschen C, Dimmeler S, Zeiher AM. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J. 2006
  • Schmidt-Lucke C, S Fichtlscherer, A Aicher, C Tschöpe, H-P Schultheiss, A M Zeiher, S Dimmeler. Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol. PLoS ONE. 2010
  • Schmidt-Lucke C, Stephan Fichtlscherer, Lothar Rössig, Ulrike Kämper, Stefanie Dimmeler. Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis. 2010
  • GP Fadini, Maruyama S, Ozaki T, Taguchi A, Meigs J, Dimmeler S, Zeiher A, de Kreutzenberg S, Avogaro A, Nickenig G, Schmidt-Lucke C, Werner N. Circulating progenitor cell count for cardiovascular risk stratification. A pooled analysis. PLoS ONE. 2010

Going new ways. Unusual thinking. Free from conventions.

Human parvovirus B19 (B19V) usually causes only a self-limiting disease. In rare cases, the disease takes a fatal course. B19V is the pathogen most frequently associated with inflammatory cardiomyopathy. The pathogen infects vascular regenerating cells (endothelial progenitor cells), leading to vascular damage and subsequent decreased blood flow to an organ. We demonstrate for the first time a treatment approach to reduce B19V-induced vascular damage by protecting the progenitor cells. This approach forms the basis for the development of an effective B19V therapy.

List of publications
  • Schmidt-Lucke C, Zobel T, Escher F, Tschöpe C, Lassner D, Kühl U, Gubbe K, Volk HD, Schultheiss HP. Human parvovirus B19 (B19V) up-regulates CXCR4 surface expression of circulating angiogenic cells: implications for cardiac ischemia in B19V cardiomyopathy. J Infect Dis. 2018
  • Schmidt-Lucke C, Spillmann F, Bock T, Kühl U, Van Linthout S, Schultheiss HP, Tschöpe C. Interferon-beta modulates endothelial damage in patients with cardiac persistence of parvovirus B19. J Infect Dis. 2010
  • Pozzuto T, von Kietzell K, Bock T, Schmidt-Lucke C, Poller W, Zobel T, Lassner D, Zeichhardt H, Weger S, Fechner H. Transactivation of human parvovirus B19 gene expression in endothelial cells by adenoviral helper functions. Virology. 2011
  • Schmidt-Lucke C, Escher F, Van Linthout S, Kühl U, Miteva K, Ringe J, Zobel T, Schultheiss HP, Tschöpe C. Cardiac migration of endogenous mesenchymal stromal cells in patients with inflammatory cardiomyopathy. Mediators Inflamm. 2015
  • Schmidt-Lucke C, Zobel T, Schrepfer S, Kühl U, Wang D, Klingel K, Becher PM, Fechner H, Pozzuto T, Van Linthout S, Lassner D, Spillmann F, Escher F, Holinski S, Volk HD, Schultheiss HP, Tschöpe C. Impaired endothelial regeneration through human parvovirus B19-infected circulating angiogenic cells in cardiomyopathy. J Infect Dis. 2015
  • Zobel T, Bock CT, Kühl U, Rohde M, Lassner D, Schultheiss HP, Schmidt-Lucke C. Telbivudine Reduces Parvovirus B19-Induced Apoptosis in Circulating Angiogenic Cells. Viruses. 2019

Change policies.

The ACE trial was an investigator-initiated study with the aim of expanding the indication of enoxaparin. In this randomized, prospective, multicenter study, enoxaparin was shown to be noninferior to unfractionated heparin and phenprocoumon in TOE-assisted cardioversion of persistent AF.

List of publications
  • Schmidt-Lucke C, Paar WD, Stellbrink C, Nixdorff U, Hofmann T, Meurer J, Grewe R, Daniel WG, Hanrath P, Mugge A, Klein HU, Schmidt-Lucke JA. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Thromb Res. 2007
  • Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation. 2004
  • Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA. Use of subcutaneous enoxaparin compared to intravenous heparin and oral phenprocoumon in the setting of cardioversion - the ACE study (Anticoagulation in Cardioversion using Enoxaparin). Card Electrophysiol Rev. 2003
  • Schadlich PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C, Brecht JG. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany. Am J Cardiovasc Drugs. 2007

Sound knowledge in theory and practice - book contributions

Recognition in the professional world.


Harrison's Internal Medicine is a highly renowned, comprehensive work in the German-speaking world, reflecting the highest standards of quality in medicine. The standard work in the Anglo-American world has enjoyed undisputed trust since 1950. The 17th and 18th editions of this encyclopedia of human medicine have been updated by 300 specialists in their fields and have been adapted to German diagnostic and therapeutic standards. Two innovative chapters on stem cell biology and on applications in clinical medicine were entrusted to the expertise of the founder in two successive editions.

List of publications
  • Schmidt-Lucke C. Regenerative medicine, stem cell biology and applications of stem cell biology in clinical medicine, in Harrison 18th edition; ABW, 2016.
  • Schmidt-Lucke C. Regenerative medicine, stem cell biology and applications of stem cell biology in clinical medicine, in Harrison 18th edition; ABW, 2012.
  • Schmidt-Lucke C. Regenerative medicine, stem cell biology and applications of stem cell biology in clinical medicine, in Harrison 17th edition; ABW, 2009.

The digitization of the healthcare market will revolutionize it as only the introduction of antibiotics probably did before. Medical apps are increasingly influencing our behavior. Despite a huge amount of medical apps, only a very small number have proven their usefulness or comply with the strict German and European regulations of a medical device. We offer support and services for developers and companies who want to take on the challenges of this disruptive technology.

List of publications
  • Schmidt-Lucke C. Medical apps between lifestyle and medical device. Going public, 2016.
  • Schmidt-Lucke C. Starting up with a medical app. Starting up, 2017.

With over 1000 pharmacology questions in the field of internal medicine and cardiology, students can prepare specifically for their oral exams. The effective way to always have the right answer. Modern study techniques to learn the extensive material for the exam and have it ready to treat the patient!

List of publications
  • Aicher A, Adler K, Schmidt-Lucke C and Brenner W. Pharmacology in question and answer. Urban & Fischer Verlag, Munich - Jena, 2005

Principles and Practice of Panvascular Medicine by editors Peter Lanzer and Eric J. Topol covers the fields of cardiology, cardiac surgery, vascular surgery, radiology, neurology, neurosurgery, and vascular medicine, among others. This will provide interdisciplinary and holistic perspectives of modern vascular medicine. Young colleagues and specialists are addressed. The founder was entrusted with fundamental contents of vascular medicine.

List of publications
  • Schmidt-Lucke C. Peripheral Artery Physiology and Pathophysiology: Special Considerations, in: Principles and Practice of Panvascular Medicine (eds. Lanzer P, Topol E), Springer-Verlag, Heidelberg-New York, 2002.
  • Schmidt-Lucke C. Microperfusion disorders in peripheral arterial occlusive disease. Med World 53: 206 -10, 2002

Show the medical benefits of your product

With our many years of experience and expertise, we offer effective solutions to demonstrate the medical benefits of your product.

From the conception to the execution of preclinical and clinical investigations, we support you with customized services.

Find out how MEDIACC can help you achieve reimbursability for your products.